A Phase I/II Study to Evaluate the Safety Pharmacodynamics and Efficacy of Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to identify the best dose of entinostat when combined with bevacizumab and atezolizumab and to find out what side effects are caused by the combination of these drugs in patients with renal cell carcinoma.
Description
The purpose of this study is to identify the best dose of entiostat when combined with bevacizumab and atezolizumab and to find out what side effects are caused by the combination of these drugs in patients with renal cell carcinoma.
Details
| Condition | renal cell carcinoma |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX7389 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.